**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**1. NAME OF THE MEDICINAL PRODUCT**

Levetiracetam Hospira 100 mg/ml concentrate for solution for infusion

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains 100 mg of levetiracetam.

Each 5 ml vial contains 500 mg of levetiracetam.

Excipient with known effect:

Each vial contains 19 mg of sodium.

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Concentrate for solution for infusion (sterile concentrate).

Clear, colourless solution.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Levetiracetam Hospira is indicated as adjunctive therapy

* in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
* in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
* in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.

**4.2 Posology and method of administration**

Posology

Levetiracetam therapy can be initiated with either intravenous or oral administration.

Conversion to or from oral to intravenous administration can be done directly without titration. The total daily dose and frequency of administration should be maintained.

*Partial onset seizures*

The recommended dosing for monotherapy (from 16 years of age) and adjunctive therapy is the same; as outlined below.

*All indications*

*Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more*

The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. However, a lower initial dose of 250 mg twice daily may be given based on physician assessment of seizure reduction versus potential side effects. This can be increased to 500 mg twice daily after two weeks.

Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 250 mg or 500 mg twice daily increases or decreases every two to four weeks.

*Adolescents (12 to 17 years) weighing below 50 kg and children from 4 years of age*

The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight, age and dose. Refer to *Paediatric population* section for dosing adjustments based on weight.

Duration of treatment

There is no experience with administration of intravenous levetiracetam for longer period than 4 days.

Discontinuation

If levetiracetam has to be discontinued it is recommended to withdraw it gradually (*e.g*. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighing less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).

Special populations

*Elderly (65 years and older)*

Adjustment of the dose is recommended in elderly patients with compromised renal function (see “Renal impairment” below).

*Renal impairment*

The daily dose must be individualised according to renal function.

For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, the following formula:

[140‑age (years)] x weight (kg)

CLcr (ml/min) = ----------------------------------------- (x 0.85 for women)

72 x serum creatinine (mg/dl)

Then CLcr is adjusted for body surface area (BSA) as follows:

CLcr (ml/min)

CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73

BSA subject (m2)

Dosing adjustment for adult and adolescent patients weighing more than 50 kg with impaired renal function:

|  |  |  |
| --- | --- | --- |
| Group | Creatinine clearance (ml/min/1.73m2) | Dose and frequency |
| Normal | ≥ 80 | 500 to 1,500 mg twice daily |
| Mild | 50‑79 | 500 to 1,000 mg twice daily |
| Moderate | 30‑49 | 250 to 750 mg twice daily |
| Severe | < 30 | 250 to 500 mg twice daily |
| End-stage renal disease patients undergoing dialysis(1) | - | 500 to 1,000 mg once daily(2) |

(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.

(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.

For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.

The CLcrin ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents and children using the following formula (Schwartz formula):

Height (cm) x ks

CLcr (ml/min/1.73 m2) = ------------------------------------

Serum Creatinine (mg/dl)

ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male

Dosing adjustment for children and adolescent patients weighing less than 50 kg with impaired renal function:

|  |  |  |
| --- | --- | --- |
| Group | Creatinine clearance  (ml/min/1.73 m2) | Dose and frequency |
| Children from 4 years and adolescents weighing less than 50 kg |
| Normal | ≥ 80 | 10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily |
| Mild | 50‑79 | 10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily |
| Moderate | 30‑49 | 5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily |
| Severe | < 30 | 5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily |
| End-stage renal disease patients undergoing dialysis | -- | 10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily (1) (2) |

1. A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.
2. Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.

*Hepatic impairment*

No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency.

Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2.

Paediatric population

The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.

*Monotherapy*

The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.

No data are available.

*Adolescents (16 and 17 years of age) weighing 50 kg or more with partial onset seizures with or without secondary generalisation with newly diagnosed epilepsy*

Please refer to the above section on *Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more*.

*Add-on therapy for children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg*

The initial therapeutic dose is 10 mg/kg twice daily.

Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used for all indications.

Dose in children 50 kg or greater is the same as in adults for all indications.

Please refer to the above section on *Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more* for all indications.

Dose recommendations for children and adolescents:

|  |  |  |
| --- | --- | --- |
| Weight | Starting dose:  10 mg/kg twice daily | Maximum dose:  30 mg/kg twice daily |
| 15 kg(1) | 150 mg twice daily | 450 mg twice daily |
| 20 kg(1) | 200 mg twice daily | 600 mg twice daily |
| 25 kg | 250 mg twice daily | 750 mg twice daily |
| From 50 kg(2) | 500 mg twice daily | 1,500 twice daily |

(1) Children 25 kg or less should preferably start the treatment with levetiracetam 100 mg/ml oral solution.

(2) Dose in children and adolescents 50 kg or more is the same as in adults.

*Add-on therapy for infants and children less than 4 years*

The safety and efficacy of Levetiracetam Hospira concentrate for solution for infusion in infants and children less than 4 years have not been established.

Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.

Method of administration

Levetiracetam Hospira concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15‑minute intravenous infusion (see section 6.6).

**4.3 Contraindications**

Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.

**4.4 Special warnings and precautions for use**

Renal impairment

The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).

Acute kidney injury

The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.

Blood cell counts

Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (section 4.8).

Suicide

Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta‑analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.

Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.

Abnormal and aggressive behaviours

Levetiracetam may cause psychotic symptoms and behavioural abnormalities including irritability and aggressiveness. Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. If such behaviours are noticed, treatment adaptation or gradual discontinuation should be considered. If discontinuation is considered, please refer to section 4.2.

Worsening of seizures

As with other types of antiepileptic drugs, levetiracetam may rarely exacerbate seizure frequency or severity. This paradoxical effect was mostly reported within the first month after levetiracetam initiation or increase of the dose and was reversible upon drug discontinuation or dose decrease. Patients should be advised to consult their physician immediately in case of aggravation of epilepsy. Lack of efficacy or seizure worsening has for example been reported in patients with epilepsy associated with sodium voltage-gated channel alpha subunit 8 (SCN8A) mutations.

Electrocardiogram QT interval prolongation

Rare cases of ECG QT interval prolongation have been observed during the post-marketing surveillance. Levetiracetam should be used with caution in patients with QTc-interval prolongation, in patients concomitantly treated with drugs affecting the QTc-interval, or in patients with relevant pre-existing cardiac disease or electrolyte disturbances.

Paediatric population

Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.

Excipients

This medicinal product contains 19 mg of sodium per vial. The maximum single dose (corresponding to 1,500 mg levetiracetam) contains 57 mg of sodium, equivalent to 2.85% of the WHO maximum recommended daily intake (RDI) of 2 g sodium for an adult. To be taken into consideration by patients on a controlled sodium diet.

This medicinal product may be diluted with sodium-containing solutions (see section 4.2) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.

**4.5 Interaction with other medicinal products and other forms of interaction**

Antiepileptic medicinal products

Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.

As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.

A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20% higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.

Probenecid

Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.

Methotrexate

Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.

Oral contraceptives and other pharmacokinetics interactions

Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.

Alcohol

No data on the interaction of levetiracetam with alcohol are available.

**4.6 Fertility, pregnancy and lactation**

Women of child bearing potential

Specialist advice should be given to women who are of childbearing potential. Treatment with levetiracetam should be reviewed when a woman is planning to become pregnant. As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.

Pregnancy

A large amount of post-marketing data on pregnant women exposed to levetiracetam monotherapy (more than 1,800, among which in more than 1,500 exposure occurred during the 1st trimester) do not suggest an increase in the risk for major congenital malformations. Only limited evidence is available on the neurodevelopment of children exposed to levetiracetam monotherapy in utero. However, current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays.

Levetiracetam can be used during pregnancy, if after careful assessment it is considered clinically needed. In such case, the lowest effective dose is recommended.

Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured.

Breastfeeding

Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.

Fertility

No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.

**4.7 Effects on ability to drive and use machines**

Levetiracetam has minor or moderate influence on the ability to drive and use machines. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, *e.g*. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.

**4.8 Undesirable effects**

Summary of the safety profile

The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The adverse reaction profile presented below is based on the analysis of pooled placebo‑controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications. Since there was limited exposure for levetiracetam intravenous use and since oral and intravenous formulations are bioequivalent, the safety information of levetiracetam intravenous will rely on levetiracetam oral use.

Tabulated list of adverse reactions

Adverse reactions reported in clinical studies (adults, adolescents, children and infants > 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000).

| **MedDRA SOC** | **Frequency category** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Very common** | **Common** | **Uncommon** | **Rare** | **Very rare** |
| Infections and infestations | Nasopharyngitis |  |  | Infection |  |
| Blood and lymphatic system disorders |  |  | Thrombocytopenia, leukopenia | Pancytopenia, neutropenia,  agranulocytosis |  |
| Immune system disorders |  |  |  | Drug reaction with eosinophilia and systemic symptoms (DRESS)(1),  Hypersensitivity (including angioedema and anaphylaxis) |  |
| Metabolism and nutrition disorders |  | Anorexia | Weight decreased, weight increase | Hyponatraemia |  |
| Psychiatric disorders |  | Depression, hostility/  aggression, anxiety, insomnia, nervousness/irritability | Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation | Completed suicide, personality disorder, thinking abnormal, delirium | Obsessive compulsive disorder(2) |
| Nervous system disorders | Somnolence, headache | Convulsion, balance disorder, dizziness, lethargy, tremor | Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention | Choreoathetosis, dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures aggravated, Neuroleptic malignant syndrome(3) |  |
| Eye disorders |  |  | Diplopia, vision blurred |  |  |
| Ear and labyrinth disorders |  | Vertigo |  |  |  |
| Cardiac disorders |  |  |  | Electrocardiogram QT prolonged |  |
| Respiratory, thoracic and mediastinal disorders |  | Cough |  |  |  |
| Gastrointestinal disorders |  | Abdominal pain, diarrhoea, dyspepsia, vomiting, nausea |  | Pancreatitis |  |
| Hepatobiliary disorders |  |  | Liver function test abnormal | Hepatic failure, hepatitis |  |
| Renal and Urinary disorders |  |  |  | Acute kidney injury |  |
| Skin and subcutaneous tissue disorders |  | Rash | Alopecia, eczema, pruritus | Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme |  |
| Musculoskeletal and connective tissue disorders |  |  | Muscular weakness, myalgia | Rhabdomyolysis and blood creatine phosphokinase increased(3) |  |
| General disorders and administration site conditions |  | Asthenia/fatigue |  |  |  |
| Injury, poisoning and procedural complications |  |  | Injury |  |  |

(1) See Description of selected adverse reactions.

(2) Very rare cases of development of obsessive-compulsive disorders (OCD) in patients with underlying history of OCD or psychiatric disorders have been observed in post-marketing surveillance.

(3) Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.

Description of selected adverse reactions

*Multiorgan hypersensitivity reactions*

Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) have been reported rarely in patients treated with levetiracetam. Clinical manifestations may develop 2 to 8 weeks after starting treatment. These reactions are variable in expression, but typically present with fever, rash, facial oedema, lymphadenopathies, haematologic abnormalities and can be associated with involvement of different organ systems, mostly the liver. If multiorgan hypersensitivity reaction is suspected, levetiracetam should be discontinued.

The risk of anorexia is higher when levetiracetam is co-administered with topiramate.

In several cases of alopecia, recovery was observed when levetiracetam was discontinued.

Bone marrow suppression was identified in some of the cases of pancytopenia.

Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.

Paediatric population

In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were treated with levetiracetam in placebo-controlled studies. In patients aged 4‑16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.

In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.

The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.

A double‑blind, placebo‑controlled paediatric safety study with a non‑inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that levetiracetam was not different (non-inferior) from placebo with regard to the change from baseline of the Leiter‑R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL – Achenbach Child Behaviour Checklist). However, subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](https://www.ema.europa.eu/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx).

**4.9 Overdose**

Symptoms

Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses.

Management of overdose

There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.

The active substance, levetiracetam, is a pyrrolidone derivative (S‑enantiomer of α‑ethyl‑2‑oxo‑1‑pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.

Mechanism of action

The mechanism of action of levetiracetam still remains to be fully elucidated. *In vitro* and *in vivo* experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.

*In vitro* studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β‑carbolines. Furthermore, levetiracetam has been shown in *in vitro* studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.

Pharmacodynamic effects

Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.

In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.

Clinical efficacy and safety

*Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.*

In adults, levetiracetam efficacy has been demonstrated in 3 double‑blind, placebo‑controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6% for patients on placebo.

Paediatric population

In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo‑controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).

44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week. With continued long‑term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.

35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.

*Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.*

Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine-controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400‑1,200 mg/day or levetiracetam 1,000‑3,000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.

Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine‑CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI: ‑7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively).

In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).

*Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.*

Levetiracetam efficacy was established in a double-blind, placebo‑controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.

In this study, levetiracetam, dose was 3,000 mg/day given in 2 divided doses. 58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. With continued long‑term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year.

*Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.*

Levetiracetam efficacy was established in a 24‑week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic‑clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3,000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.

72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. With continued long‑term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic‑clonic seizures for at least 1 year.

**5.2 Pharmacokinetic properties**

The pharmacokinetic profile has been characterized following oral administration. A single dose of 1,500 mg levetiracetam diluted in 100 ml of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1,500 mg levetiracetam oral intake, given as three 500 mg tablets.

The intravenous administration of doses up to 4,000 mg diluted in 100 ml of 0.9% sodium chloride infused over 15 minutes and doses up to 2,500 mg diluted in 100 ml of 0.9% sodium chloride infused over 5 minutes was evaluated. The pharmacokinetic and safety profiles did not identify any safety concerns.

Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra‑ and inter‑subject variability. There is no modification of the clearance after repeated administration. The time independent pharmacokinetic profile of levetiracetam was also confirmed following 1,500 mg intravenous infusion for 4 days with twice daily dosing.

There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.

Adults and adolescents

Distribution

Peak plasma concentration (Cmax) observed in 17 subjects following a single intravenous dose of 1,500 mg infused over 15 minutes was 51 ± 19 micrograms/ml (arithmetic average ± standard deviation).

No tissue distribution data are available in humans.

Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10%).

The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.

Biotransformation

Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.

Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6% of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose). Other unidentified components accounted only for 0.6% of the dose.

No enantiomeric interconversion was evidenced *in vivo* for either levetiracetam or its primary metabolite.

*In vitro*, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the *in vitro* glucuronidation of valproic acid.

In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The *in vitro* data and *in vivo* interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected *in vivo*. Therefore, the interaction of levetiracetam with other substances, or *vice versa,* is unlikely.

Elimination

The plasma half-life in adults was 7±1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.

The major route of excretion was via urine, accounting for a mean 95% of the dose (approximately 93% of the dose was excreted within 48 hours). Excretion *via* faeces accounted for only 0.3% of the dose.

The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66% and 24% of the dose, respectively during the first 48 hours.

The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration.

Levetiracetam elimination is correlated to creatinine clearance.

Elderly

In the elderly, the half-life is increased by about 40% (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).

Renal impairment

The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).

In anuric end-stage renal disease adult subjects the half‑life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.

The fractional removal of levetiracetam was 51% during a typical 4‑hour dialysis session.

Hepatic impairment

In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50% due to a concomitant renal impairment (see section 4.2).

Paediatric population

*Children (4 to 12 years)*

The pharmacokinetics in paediatric patients has not been investigated after intravenous administration.

However, based on the pharmacokinetic characteristics of levetiracetam, the pharmacokinetics in adults after intravenous administration and the pharmacokinetics in children after oral administration, the exposure (AUC) of levetiracetam is expected to be similar in paediatric patients aged 4 to 12 years after intravenous and oral administration.

Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half‑life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30% higher than in epileptic adults.

Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.

**5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.

Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.

No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1,800 mg/kg/day (x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.

Two embryo-foetal development (EFD) studies were performed in rats at 400, 1,200 and 3,600 mg/kg/day. At 3,600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on embryomortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3,600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1,200 mg/kg/day for foetuses.

Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day. The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies. The NOAEL was < 200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m2 basis).

A peri‑ and post‑natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day. The NOAEL was ≥1,800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m2 basis).

Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6‑17 the MRHD on a mg/m2 basis)

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Sodium acetate trihydrate

Glacial acetic acid

Sodium chloride

Water for injections

**6.2 Incompatibilities**

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

**6.3 Shelf life**

2 years

Chemical and physical in-use stability of the diluted product stored in PVC bags has been demonstrated for 24 hours at 30 °C and at 2-8 °C. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage time and conditions are the responsibility of the user.

**6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions.

For storage conditions of the diluted medicinal product, see section 6.3.

**6.5 Nature and contents of container**

5 ml glass vial (type I) with bromobutyl coated rubber stoppers and an aluminium flip-off seal.

Each carton contains 10 or 25 vials.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

See Table 1 for the recommended preparation and administration of Levetiracetam Hospira concentrate for solution for infusion to achieve a total daily dose of 500 mg, 1,000 mg, 2,000 mg, or 3,000 mg in two divided doses.

Table 1. Preparation and administration of Levetiracetam Hospira concentrate for solution for infusion

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Dose** | **Withdrawal Volume** | **Volume of Diluent** | **Infusion Time** | **Frequency of Administration** | **Total Daily Dose** |
| 250 mg | 2.5 ml (half 5 ml vial) | 100 ml | 15 minutes | Twice daily | 500 mg/day |
| 500 mg | 5 ml (one 5 ml vial) | 100 ml | 15 minutes | Twice daily | 1,000 mg/day |
| 1,000 mg | 10 ml (two 5 ml vials) | 100 ml | 15 minutes | Twice daily | 2,000 mg/day |
| 1,500 mg | 15 ml (three 5 ml vials) | 100 ml | 15 minutes | Twice daily | 3,000 mg/day |

This medicinal product is for single use only, any unused solution should be discarded.

Levetiracetam Hospira concentrate for solution for infusion was found to be physically compatible and chemically stable when mixed with the following diluents:

* Sodium chloride 9 mg/ml (0.9%) solution for injection
* Lactated Ringer’s solution for injection
* Dextrose 50 mg/ml (5%) solution for injection

Medicinal product with particulate matter or discoloration should not be used.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

1050 Bruxelles

Belgium

**8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/13/889/001

EU/1/13/889/002

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 08 January 2014

Date of latest renewal: 20 November 2018

**10 DATE OF REVISION OF THE TEXT**

{MM/YYYY}

Detailed information on this medicinal product is available on the website of the European Medicines

Agency <https://www.ema.europa.eu>.

**ANNEX II**

**A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

**D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

**A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer responsible for batch release

Pfizer Service Company BV

Hermeslaan 11

1932 Zaventem

Belgium

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to medical prescription.

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

* **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

**D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

* **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

* At the request of the European Medicines Agency;
* Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**

**A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**Box of 10 or 25 vials**

**1. NAME OF THE MEDICINAL PRODUCT**

Levetiracetam Hospira 100 mg/ml concentrate for solution for infusion

levetiracetam

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

One vial contains 500 mg/5 ml levetiracetam.

Each ml contains 100 mg levetiracetam.

**3. LIST OF EXCIPIENTS**

Other ingredients include sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections. See the package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Concentrate for solution for infusion

500 mg/5 ml

10 vials

25 vials

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Intravenous use

Dilute before use

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

Use immediately after dilution.

**9. SPECIAL STORAGE CONDITIONS**

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

1050 Bruxelles

Belgium

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/13/889/001

EU/1/13/889/002

**13. BATCH NUMBER**

BN

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted.

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC

SN

NN

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Vial of 5 ml**

**1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

Levetiracetam Hospira 100 mg/ml sterile concentrate

levetiracetam

IV

**2. METHOD OF ADMINISTRATION**

**3. EXPIRY DATE**

EXP

Use immediately after dilution.

**4. BATCH NUMBER**

BN

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

500 mg/5 ml

**6. OTHER**

**B. PACKAGE LEAFLET**

**Package leaflet: Information for the patient**

**Levetiracetam Hospira 100 mg/ml concentrate for solution for infusion**

levetiracetam

**Read all of this leaflet carefully before you or your child start using this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.

- If you have any further questions, ask your doctor or pharmacist.

- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

- If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

**What is in this leaflet**

1. What Levetiracetam Hospira is and what it is used for

2. What you need to know before you are given Levetiracetam Hospira

3. How Levetiracetam Hospira is given

4. Possible side effects

5. How to store Levetiracetam Hospira

6. Contents of the pack and other information

**1. What Levetiracetam Hospira is and what it is used for**

Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).

Levetiracetam Hospira is used:

* on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.
* as an add-on to other antiepileptic medicines to treat:
* partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age.
* myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
* primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Levetiracetam Hospira concentrate for solution for infusion is an alternative for patients when administration of the antiepileptic levetiracetam medicine by mouth is temporarily not feasible.

**2. What you need to know before you are given Levetiracetam Hospira**

**Do not use Levetiracetam Hospira**

* If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6).

**Warnings and precautions**

Talk to your doctor before you are given Levetiracetam Hospira

* If you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if your dose should be adjusted.
* If you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor.
* A small number of people being treated with anti-epileptics such as Levetiracetam Hospira have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.
* If you have a family or medical history of irregular heart rhythm (visible on an electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.

Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:

* Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour.
* Aggravation of epilepsy:

Your seizures may rarely become worse or happen more often, mainly during the first month after the start of the treatment or increase of the dose.

In a very rare form of early-onset epilepsy (epilepsy associated with SCN8A mutations) that causes multiple types of seizures and loss of skills you may notice that the seizures remain present or are becoming worse during your treatment.

If you experience any of these new symptoms while taking Levetiracetam Hospira, see a doctor as soon as possible.

**Children and adolescents**

* Levetiracetam Hospira is not indicated in children and adolescents below 16 years on its own (monotherapy).

**Other medicines and Levetiracetam Hospira**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.

**Pregnancy and breast‑feeding**

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. You should not stop your treatment without discussing this with your doctor. A risk of birth defects for your unborn child cannot be completely excluded. Breast-feeding is not recommended during treatment.

**Driving and using machines**

Levetiracetam Hospira may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.

**Levetiracetam Hospira contains sodium**

One maximum single dose of Levetiracetam Hospira concentrate contains 57 mg of sodium (19 mg of sodium per vial) equivalent to 2.85% of the recommended maximum daily dietary intake of sodium for an adult. This should be taken into consideration if you are on a controlled sodium diet.

**3. How Levetiracetam Hospira is given**

A doctor or a nurse will administer you Levetiracetam Hospira as an intravenous infusion.

Levetiracetam Hospira must be administered twice a day, once in the morning and once in the evening, at about the same time each day.

The intravenous formulation is an alternative to your oral administration. You can switch from the film-coated tablets or from the oral solution to the intravenous formulation or reverse directly without dose adaptation. Your total daily dose and frequency of administration remain identical.

***Adjunctive therapy and monotherapy (from 16 years of age)***

**Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more:**

Recommended dose: between 1,000 mg and 3,000 mg each day.

When you first start taking Levetiracetam Hospira, your doctor will prescribe you a **lower dose** for 2 weeks before giving you the lowest daily dose.

**Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:**

Recommended dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.

**Method and route of administration:**

Levetiracetam Hospira is for intravenous use.

The recommended dose must be diluted in at least 100 ml of a compatible diluent and infused over 15‑minutes.

For doctors and nurses, more detailed direction for the proper use of Levetiracetam Hospira is provided in section 6.

**Duration of treatment:**

* There is no experience with administration of intravenous levetiracetam for a longer period than 4 days.

**If you stop using Levetiracetam Hospira:**

If stopping treatment, as with other antiepileptic medicines, Levetiracetam Hospira should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Levetiracetam Hospira treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Hospira.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Tell your doctor immediately, or go to your nearest emergency department, if you experience:**

* weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
* swelling of the face, lips, tongue and throat (Quincke’s oedema)
* flu‑like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia), enlarged lymph nodes and the involvement of other body organs (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
* symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function
* a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (*erythema multiforme*)
* a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (*Stevens-Johnson syndrome*)
* a more severe form of rash causing skin peeling in more than 30% of the body surface (*toxic epidermal necrolysis*)
* signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.

The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.

**Very common**: may affect more than 1 in 10 people

* nasopharyngitis;
* somnolence (sleepiness), headache.

**Common:** may affect up to 1 in 10 people

* anorexia (loss of appetite);
* depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
* convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
* vertigo (sensation of rotation);
* cough;
* abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
* rash;
* asthenia/fatigue (tiredness).

**Uncommon**: may affect up to 1 in 100 people

* decreased number of blood platelets, decreased number of white blood cells;
* weight decrease, weight increase;
* suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;
* amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
* diplopia (double vision), vision blurred;
* elevated/abnormal values in a liver function test;
* hair loss, eczema, pruritus;
* muscle weakness, myalgia (muscle pain);
* injury.

**Rare**: may affect up to 1 in 1,000 people

* infection;
* decreased number of all blood cell types;
* severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat]);
* decreased blood sodium concentration;
* suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
* delirium;
* encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms);
* seizures may become worse or happen more often;
* uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
* change of the heart rhythm (Electrocardiogram);
* pancreatitis;
* liver failure, hepatitis;
* sudden decrease in kidney function;
* skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (*erythema multiforme*), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (*Stevens-Johnson syndrome*), and a more severe form causing skin peeling in more than 30% of the body surface (*toxic epidermal necrolysis*);
* rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
* limp or difficulty walking;
* combination of fever, muscle stiffness, unstable blood pressure and heart rate, confusion, low level of consciousness (may be signs of a disorder called *neuroleptic malignant syndrome*). Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.

**Very rare**: may affect up to 1 in 10,000 people

* repeated unwanted thoughts or sensations or the urge to do something over and over again (Obsessive Compulsive Disorder).

**Reporting of side effects**

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](https://www.ema.europa.eu/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Levetiracetam Hospira**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the vial and carton box after EXP:

The expiry date refers to the last day of the month.

This medicine does not require any special storage conditions.

**6. Contents of the pack and other information**

**What Levetiracetam Hospira contains**

* The active substance is called levetiracetam. Each ml contains 100 mg of levetiracetam.
* The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections (see section 2 Levetiracetam Hospira contains sodium).

**What Levetiracetam Hospira looks like and contents of the pack**

Levetiracetam Hospira concentrate for solution for infusion (sterile concentrate) is a clear, colourless solution.

Levetiracetam Hospira concentrate for solution for infusion is packed in a cardboard box containing 10 or 25 vials of 5 ml.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder**

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

1050 Bruxelles

Belgium

**Manufacturer**

Pfizer Service Company BV

Hermeslaan 11

1932 Zaventem

Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

|  |  |
| --- | --- |
| **België/Belgique/Belgien**  Pfizer NV/SA  Tél/Tel: +32 (0) 2 554 62 11 | **Lietuva**  Pfizer Luxembourg SARL filialas Lietuvoje  Tel. + 370 52 51 4000 |
| **България**  Пфайзер Люксембург САРЛ, Клон България  Тел.: +359 2 970 4333 | **Luxembourg/Luxemburg**  Pfizer NV/SA  Tél/Tel: +32 (0) 2 554 62 11 |
| **Česká republika**  Pfizer, spol. s r.o.  Tel: +420-283-004-111 | **Magyarország**  Pfizer Kft.  Tel: + 36 1 488 37 00 |
| **Danmark**  Pfizer ApS  Tlf.: + 45 44 20 11 00 | **Malta**  Drugsales Ltd  Tel: + 356 21 419 070/1/2 |
| **Deutschland**  PFIZER PHARMA GmbH  Tel: +49 (0)30 550055-51000 | **Nederland**  Pfizer bv  Tel: +31 (0)800 63 34 636 |
| **Eesti**  Pfizer Luxembourg SARL Eesti filiaal  Tel: +372 666 7500 | **Norge**  Pfizer AS  Tlf: +47 67 52 61 00 |
| **Ελλάδα**  Pfizer ΕΛΛΑΣ A.E.  Τηλ.: +30 210 6785 800 | **Österreich**  Pfizer Corporation Austria Ges.m.b.H.  Tel: +43 (0)1 521 15-0 |
| **España**  Pfizer, S.L.  Tel: +34 91 490 99 00 | **Polska**  Pfizer Polska Sp. z o.o.  Tel: +48 22 335 61 00 |
| **France**  Pfizer  Tél: + 33 (0)1 58 07 34 40 | **Portugal**  Laboratórios Pfizer, Lda.  Tel: +351 21 423 55 00 |
| **Hrvatska**  Pfizer Croatia d.o.o.  Tel: +385 1 3908 777 | **România**  Pfizer România S.R.L.  Tel: +40 (0)21 207 28 00 |
| **Ireland**  Pfizer Healthcare Ireland Unlimited Company  Tel: 1800 633 363 (toll free)  +44 (0) 1304 616161 | **Slovenija**  Pfizer Luxembourg SARL  Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana  Tel: +386 (0)1 52 11 400 |
| **Ísland**  Icepharma hf.  Sími: +354 540 8000 | **Slovenská republika**  Pfizer Luxembourg SARL, organizačná zložka  Tel: +421–2–3355 5500 |
| **Italia**  Pfizer S.r.l.  Tel: +39 06 33 18 21 | **Suomi/Finland**  Pfizer Oy  Puh/Tel: +358 (0)9 430 040 |
| **Κύπρος**  Pfizer Ελλάς Α.Ε. (Cyprus Branch)  Τηλ.: +357 22817690 | **Sverige**  Pfizer AB  Tel: +46 (0)8 550 520 00 |
| **Latvija**  Pfizer Luxembourg SARL filiāle Latvijā  Tel.: + 371 670 35 775 |  |

**This leaflet was last revised in month YYYY.**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site: <https://www.ema.europa.eu>.

---------------------------------------------------------------------------------------------------------------------------

**The following information is intended for healthcare professionals only:**

Directions for the proper use of Levetiracetam Hospira is provided in section 3.

One vial of Levetiracetam Hospira concentrate contains 500 mg levetiracetam (5 ml concentrate of 100 mg/ml). See Table 1 for the recommended preparation and administration of Levetiracetam Hospira concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.

Table 1. Preparation and administration of Levetiracetam Hospira concentrate

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Dose** | **Withdrawal Volume** | **Volume of Diluent** | **Infusion Time** | **Frequency of administration** | **Total Daily Dose** |
| 250 mg | 2.5 ml (half 5 ml vial) | 100 ml | 15 minutes | Twice daily | 500 mg/day |
| 500 mg | 5 ml (one 5 ml vial) | 100 ml | 15 minutes | Twice daily | 1,000 mg/day |
| 1,000 mg | 10 ml (two 5 ml vials) | 100 ml | 15 minutes | Twice daily | 2,000 mg/day |
| 1,500 mg | 15 ml (three 5 ml vials) | 100 ml | 15 minutes | Twice daily | 3,000 mg/day |

This medicinal product is for single use only, any unused solution should be discarded.

In use shelf life:

Chemical and physical in-use stability of the diluted product stored in PVC bags has been demonstrated for 24 hours at 30 °C and at 2-8 °C. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage time and conditions are the responsibility of the user.

Levetiracetam Hospira concentrate was found to be physically compatible and chemically stable when mixed with the following diluents:

* Sodium chloride 9 mg/ml (0.9%) solution for injection
* Lactated Ringer’s solution for injection
* Dextrose 50 mg/ml (5%) solution for injection